A personalised mRNA cancer vaccine has delivered a major breakthrough in oncology, with Merck and Moderna reporting positive results from a large Phase 3 trial involving patients with high-risk melanoma.
The companies said their bespoke mRNA vaccine, administered alongside Merck’s immunotherapy Keytruda after surgery, significantly reduced the risk of cancer recurrence and distant metastasis compared with Keytruda alone.
The results from the Phase 3 INTerpath-001 trial could mark an important turning point for personalised cancer treatment and the broader use of mRNA technology beyond infectious diseases.
What did the Merck-Moderna cancer vaccine trial find?
The INTerpath-001 study enrolled 1,137 patients with stage IIB to stage IV melanoma whose tumours had been surgically removed.
Patients received either Keytruda alone or Keytruda combined with an individualised mRNA vaccine designed specifically around mutations found in their tumours.
The trial met both its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival.
The companies have not yet released detailed hazard ratios, saying the full findings will be presented at a medical meeting. However, the trial was stopped early after an interim analysis showed sufficient evidence of efficacy.
The announcement triggered a sharp market reaction, with Moderna shares reportedly surging while Merck also recorded a significant rise.
Why is this a big deal for cancer treatment?
The significance lies in the fact that this is a personalised neoantigen therapy.
Unlike traditional cancer vaccines that target proteins commonly found on tumour cells, a personalised neoantigen vaccine is created using mutations unique to an individual patient’s tumour.
Cancer cells accumulate genetic mutations. Some of these mutations create abnormal proteins known as neoantigens, which can act as molecular markers that distinguish cancer cells from healthy cells.
The personalised vaccine is designed to train the patient’s immune system to recognise those specific markers.
In this approach, doctors can sequence a patient’s tumour, identify promising neoantigens and create an mRNA treatment carrying instructions for those targets.
How does the mRNA vaccine work with Keytruda?
The two treatments have complementary roles.
The personalised vaccine essentially teaches the immune system what to attack by presenting tumour-specific neoantigens.
Keytruda, meanwhile, is a checkpoint inhibitor. It helps prevent cancer cells from suppressing T-cell activity, allowing immune cells to remain active against the tumour.
In simple terms, the vaccine helps the immune system identify the enemy, while Keytruda helps prevent that immune response from being switched off.
An earlier Phase 2b study had already suggested that the combination could substantially reduce recurrence and distant metastasis compared with Keytruda alone. The much larger Phase 3 trial now provides stronger evidence for the approach.
Why cancer vaccines have struggled in the past
Cancer vaccines have been studied for decades, but many earlier candidates failed to deliver meaningful benefits in large clinical trials.
One challenge was finding a target that existed on cancer cells but not on healthy tissue. Targeting proteins that were also present in normal cells could potentially produce unwanted immune reactions, while targets that looked too similar to normal tissue could fail to generate a strong immune response.
Personalised neoantigen vaccines attempt to overcome this problem by targeting mutations specific to an individual tumour.
That makes the approach fundamentally different from an off-the-shelf vaccine designed to work in every patient.
What does the trial mean for the future of mRNA technology?
The success could also represent a major moment for the mRNA industry.
mRNA technology became globally prominent after the Covid-19 vaccines developed by Moderna and Pfizer-BioNTech demonstrated that synthetic messenger RNA could be produced at enormous scale and used to stimulate an immune response.
But researchers and investors have since been looking for evidence that mRNA could become a broader therapeutic platform.
A successful Phase 3 oncology trial provides an important piece of that evidence.
It does not mean mRNA treatments will automatically work for every disease. However, the results strengthen the case for exploring the technology in cancer and other therapeutic areas.
What could it mean for Indian cancer patients?
Melanoma is relatively uncommon in India compared with several other cancers. However, the technology behind the vaccine could eventually have wider implications.
The broader INTerpath programme is investigating personalised mRNA neoantigen treatments in cancers including lung, bladder, kidney, pancreatic and gastric cancers.
Several of these cancers represent significant health burdens in India.
If similar results are demonstrated across other tumour types, personalised mRNA therapies could eventually become relevant to a much larger patient population.
However, affordability and manufacturing capacity remain major challenges.
Personalised treatment could be expensive
Unlike conventional medicines that can be mass-produced, a personalised cancer vaccine has to be developed around an individual patient’s tumour.
The process involves tumour sequencing, computational identification of neoantigens, vaccine manufacturing and distribution.
That complex workflow could make the treatment significantly more expensive than conventional therapies, particularly in the early stages of adoption.
For countries such as India, the availability of domestic manufacturing and the development of faster, lower-cost production systems could therefore determine how accessible personalised cancer vaccines eventually become.
A new chapter for cancer vaccines
The Merck-Moderna results do not mean cancer has been defeated, nor do they guarantee that personalised mRNA vaccines will succeed against every cancer.
But the INTerpath-001 results represent a significant milestone.
For decades, scientists have tried to harness the immune system to recognise and destroy cancer cells more precisely. A personalised mRNA vaccine that can identify a patient’s tumour-specific mutations and work alongside an established immunotherapy could bring that concept closer to routine clinical practice.
The next question is whether the success seen in melanoma can be replicated across other cancers. If it can, personalised mRNA treatment could become one of the defining developments in oncology over the next decade.
